HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Cisplatin

SUSPENDED · PHASE2 · Resectable Intrahepatic Cholangiocarcinoma

Other - evaluation of patients on first stage

Registry source

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.